When Purdue Pharma was founded in 1912, it was already a drug company with its own patented formula, and it was an early innovator in the field of biotechnology.
But the company didn’t go to the lengths needed to become a full-fledged pharmaceutical company until the late 1950s, when it launched its first line of drugs to treat epilepsy.
By the 1960s, the company was already one of the largest pharmaceutical companies in the world, and its innovations were taking on a life of their own, including the birth of the modern epilepsy drug, Epidiolex.
By 1963, the brand had become a household name, and with the help of an investment by the Rockefeller Foundation, it had expanded its pharmaceutical portfolio to include more than $20 billion in revenue in 1965 alone.
By 1965, the Epidioslex brand was also the subject of a new blockbuster movie, “Crazy Heart.”
The movie, which was based on the true story of a young woman who developed the drug, has become one of Hollywood’s most well-loved films.
But it’s hard to find any evidence that the film’s success was due to the drug itself.
In fact, there’s little to show that Epidiopax, or Epidiol, was even invented in the first place.
“It was a great idea,” says Philip Fischl, a neurologist and professor at the University of Michigan who was a key player in the development of Epidiotax.
“They had a great marketing campaign to get people to believe that it was a drug that was going to save your life, and that it had no side effects.”
The fact that the drug was so successful didn’t help its reputation, either.
Epidiones made it through FDA testing and approval in 1964 and 1965 before being pushed to the market as an epilepsy drug.
But while the company sold more than 8 million of the drugs over the next two decades, the drug never gained widespread popularity because it was only effective for a relatively small group of people.
By comparison, EpiPen has been a blockbuster for the past 20 years.
And despite the fact that EpiPens are more effective than Epidies, it’s not the only drug on the market with an addictive potential.
According to a 2012 study, Epilepsy-related deaths have quadrupled over the past decade.
It’s a problem that has been exacerbated by a lack of effective treatments.
The U.S. Food and Drug Administration (FDA) has issued numerous warnings about the potential for the drugs to increase the risk of seizures and death, and the FDA is still investigating whether they can be used to treat serious diseases.
“There’s a lot of controversy about the safety of the drug,” says Fischbacher.
“I think it’s probably the biggest safety concern.
But I don’t think it’ll go away.”
And while the EpiDrugs may have done some good in the war on epilepsy, it has also been accused of being just another marketing tool.
“People who are skeptical of the product might be a little bit disappointed that we have an Epidiac and a EpiTrex,” Fischbecker says.
“If you don’t see the big picture, that’s where they go wrong.”